AZN : Phase III Trial Of FASENRA In Eosinophilic Granulomatosis With Polyangiitis Meets Main Goal

(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said that results from the MANDARA Phase III trial showed the company's FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared to mepolizumab in patients with eosinophilic gra https://www.nasdaq.com/articles/azn-:-phase-iii-trial-of-fasenra-in-eosinophilic-granulomatosis-with-polyangiitis-meets